Gilead Sciences is now a recommended buy according to 28 ratings firms that are covering the firm.

Although one research analyst has the stock listed as a sell, and four have issued a hold, 20 are calling it a buy a two are giving it a strong buy recommendation, according to a WKRB report.

The one-year price objective among brokerages is $127.39. Shares of Gilead Sciences were down 6.28 percent on Monday, reaching $105.33, with a trading volume of 22,739,40 shares.

Gilead Sciences has experienced a 52-week low of $85.95, and its 52-week high was $123.37.

The average price over 50 days is $115.71, and $108.73 over 200 days.

Gilead Sciences issued quarterly earnings results back in late July, reported $3.15 earnings per share, beating previous estimates of $2.83. It had also earned $8.22 billion during the quarter, up 25.8 percent year over year.

In addition, the firm had a quarterly dividend that will pay at the end of September. The dividend is about $0.43 per share.

Gilead Sciences is a research-based biopharmaceutical company that is responsible for developing medicines. It focuses on liver diseases like hepatitis as well as human immunodeficiency virus (HIV).